Bristol Myers’ Opdivo clears signs of lung cancer in first-in-class pre-surgery win
Bristol Myers Squibb’s Opdivo may not be the most popular immunotherapy for treating metastatic non-small cell lung cancer, but it’s now the first to report positive...


















